title: [Effectiveness and adequacy of tolvaptan prescription in hospitalized patients].
abstract: OBJECTIVE
  To analyse the effectiveness of the use of Tolvaptan and the adequacy of Tolvaptan prescription at a tertiary level hospital.
  
  
  METHODS
  Prospective observational study of Tolvaptan prescrip - tion from October of 2010 to December of 2011.
  
  
  RESULTS
  30 patients (60.0% males) were included, 50.0% of which were diagnosed with heart failure and 30.0% with SIADH. Tolvaptan allowed achieving sodium levels higher than 135 mEq/L in 53.3% of the patients with a mean baseline value of 125.3±7.3 mEq/L. The median treatment duration was 5.0 days (interquartile range=3-45). A significant increase of uric acid associated to Tolvaptan treatment was observed. The prescription was in agreement to what has been established in GFT in 63.3% of the cases.
  
  
  CONCLUSIONS
  Tolvaptan increases sodium levels by 7.5 mEq/L, both in SIADH-associated hyponatremia and in heart failure, with an appropriate safety profile.
authors.forename: Ma D
authors.initials: MD
authors.lastname: Edo Solsona
authors.forename: J
authors.initials: J
authors.lastname: Ruiz Ramos
authors.forename: M
authors.initials: M
authors.lastname: Montero Hernández
authors.forename: I
authors.initials: I
authors.lastname: Font Noguera
authors.forename: J L
authors.initials: JL
authors.lastname: Poveda Andrés
mesh_terms: D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D004232:Diuretics / Q000008:administration & dosage / Q000627:therapeutic use; D016527:Drug Costs; D004341:Drug Evaluation; D011307:Drug Prescriptions / Q000191:economics; D004359:Drug Therapy, Combination; D005260:Female; D005665:Furosemide / Q000008:administration & dosage / Q000627:therapeutic use; D019983:Guideline Adherence; D006333:Heart Failure / Q000097:blood / Q000150:complications; D006801:Humans; D007010:Hyponatremia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D007177:Inappropriate ADH Syndrome / Q000097:blood / Q000150:complications; D007297:Inpatients; D007686:Kidney Tubules, Distal / Q000187:drug effects; D008103:Liver Cirrhosis / Q000097:blood / Q000150:complications; D008297:Male; D009318:Natriuresis / Q000187:drug effects; D010607:Pharmacy Service, Hospital / Q000191:economics / Q000706:statistics & numerical data; D017410:Practice Guidelines as Topic; D011446:Prospective Studies; D017483:Receptors, Vasopressin; D012964:Sodium / Q000097:blood; D013030:Spain; D062606:Tertiary Care Centers / Q000191:economics / Q000706:statistics & numerical data; D000077602:Tolvaptan; D014527:Uric Acid / Q000097:blood
chemical_list: C585768:AVPR2 protein, human; D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; D004232:Diuretics; D017483:Receptors, Vasopressin; D000077602:Tolvaptan; D014527:Uric Acid; D005665:Furosemide; D012964:Sodium